Trial · NCT07908381
A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV Who Are at High Risk for Severe Disease
NCT07908381, Phase 2, Phase 3, Recruiting, Enanta Pharmaceuticals, Inc
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV Who Are at High Risk for Severe Disease. Trials, record NCT07908381. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07908381
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV Who Are at High Risk for Severe Disease
- NCT number
- NCT07908381
- Status
- Recruiting
- Phases
- Phase 2, Phase 3
- Enrollment
- 860 participants, estimated
- Lead sponsor
- Enanta Pharmaceuticals, Inc
- Conditions
- RSV
- Interventions
- zelicapavir, Placebo
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to complete resolution of all 13 RSV symptoms as assessed by the Respiratory Infection Intensity and Impact Questionnaire (RiiQ) symptom scale | Day 1 through Day 21 | |
| Secondary | Number of participants with hospitalization due to RSV | Day 1 through Day 35 | |
| Secondary | Number of participants with hospitalization or death due to any cause | Day 1 through Day 35 | |
| Secondary | Number of participants who died | Day 1 through Day 35 | |
| Secondary | Number of participants with non-protocol defined medical visits for any cause | Day 1 through Day 35 | |
| Secondary | Time to complete resolution of RSV LRTD symptoms by RiiQ | Day 1 through Day 21 | |
| Secondary | Time to complete resolution of all 29 RSV parameters as assessed by RiiQ symptom scale score | Day 1 through Day 21 | |
| Secondary | Time to alleviation of LRTD symptoms by RiiQ | Day 1 through Day 21 | |
| Secondary | Time to alleviation of all 13 RSV symptoms as assessed by RiiQ | Day 1 through day 21 | |
| Secondary | Time to alleviation of all 29 RSV parameters as assessed by RiiQ | Day 1 through Day 21 |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07908381
GET https://conductscience.org/api/trials/v1/NCT07908381/registered